Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Register

Already have an account?

If you already have an IQVIA OneKey account, log in to access the myAstraZeneca websites.

Login
EN FR
FASENRA® is indicated as an add-on maintenance treatment of adult patients with severe eosinophilic asthma.

The legacy of FASENRA® (benralizumab injection)
in severe eosinophilic asthma

>120,000 patients have been treated with FASENRA® worldwide2*

  • Icon Maple leaf

    Over 5 years of experience in Canada3*

  • Icon Globe

    Authorized in
    80 countries4*

  • Icon Microscope

    15 years of clinical trial experience4*

  • Icon Patients

    Studied in almost 4000 patients in clinical trials4*

Be the first to receive the latest news and clinical information on FASENRA®.

Register for updates
Back to top

Safety information1

Clinical use:

FASENRA® is not indicated for other eosinophilic conditions or for relief of acute bronchospasm or status asthmaticus.

FASENRA® is not indicated in the pediatric population, as the efficacy and safety of FASENRA® has not been established in patients less than 18 years of age.

There is limited experience with FASENRA® in patients 65 years of age and older. No overall differences in efficacy or safety of FASENRA® were observed between geriatric and adult patients treated with FASENRA® in clinical trials. Sensitivity of some older individuals, however, cannot be excluded.

Relevant warnings and precautions:

  • FASENRA® should not be used to treat acute asthma symptoms or exacerbations
  • Abrupt corticosteroid discontinuation is not recommended
  • Need for gradual reduction in corticosteroid doses
  • Helminth infection
  • Hypersensitivity reactions
  • Pregnant and nursing women

For more information:

Please consult the Product Monograph for important information regarding adverse reactions, drug interactions, and dosing instructions which have not been discussed in the piece. The Product Monograph is also available by calling 1-800-668-6000.

* Clinical significance unknown.

References:

  1. FASENRA® Product Monograph, AstraZeneca Canada Inc.
  2. Data on file. AstraZeneca Canada Inc. Signed October 12, 2023.
  3. FASENRA® Notice of Compliance. 2018.
  4. Data on file. AstraZeneca Canada Inc. Signed November 22, 2023.
Back to top